Allogeneic hematopoietic stem cell transplantations (allo-HSCT) is often indicated in malignant hematologic diseases. Conditioning regimens, used to reduce the tumor burden and to prevent transplant rejection, are based on chemotherapy alone or combined with total body irradiation (TBI). Endocrine complications are frequent transplant-related side effects. Investigators have been well described in children studies but less in adulthood. The objective of this study is to assess retrospectively endocrine, bone and metabolic disorders in adult patients, 12 months after allo-HSCT.
No linked publications found in PubMed
Inclusion Criteria: * patients treated with allo-HSCT from 2006 to 2016 for a malignant hematologic disease * adult and in complete remission at exploration. Exclusion Criteria: * anteriority of brain radiotherapy * prior HSCT * pregnancy